Great interview with Aclarion CEO Brent Ness and MedTech Guru Thomas Hickey about Nociscan and the key accomplishments that are driving Aclarion’s success. Listen today! #ACON #ACONW #nasdaq #lowbackpain https://t.co/d1NFS4vUgf

At #ISSLS2024, researchers from the Reach Center at UCSF presented data where Nociscan AI was utilized to better understand Modic changes in patients suffering from chronic low back pain (cLBP). https://t.co/btHdmqtze1 #ACON #ACONW #nasdaq #spinesurgery #ISSLS2024

Attending NASS this week? Reach out at info@aclarion.com to meet with the Aclarion team in Chicago. #NASS2024 #ACON #ACONW #nasdaq #NASS24 #lowbackpain #spinesurgery

Evidence. Growth. Access. To date in 2024, we have already met many of our commercial goals toward our company mission of leading with clinical evidence to improve the care of cLBP. And year isn't done yet... https://t.co/gpdxemcEn7 #ACON #ACONW #nasdaq #spinesurgery #lowbackpain

We are excited to announce our new partnership with Justin Kubeck MD and Ocean Pain and Spine to deliver Nociscan to patients in the personal injury and workers compensation market in Toms River, NJ. https://t.co/04JEfesUL5 #ACON #ACONW #nasdaq #lowbackpain #spinesurgery

The CLUE trial is growing! We are thrilled to announce the launch of the second Clinical Utility and Economic (CLUE) site at Ocean Pain and Spine in Toms River, NJ with Justin Kubeck. https://t.co/au1T0uUfaC

Commitment to Clinical Evidence! We are excited to announce the launch of our multi-center CLUE Trial to quantify how often Nociscan’s AI generated biomarker data changes surgical treatment plans. https://t.co/vZgbq4QcIZ #ACON #ACONW #nasdaq #spinesurgery #lowbackpain

#Nociscan access is growing! We are thrilled to announce our commercial agreement with Sheraton Community Hospital, making Nociscan available to patients in greater Michigan with neurosurgeon John Keller #ACON #ACONW #nasdaq #spinesurgery #lowbackpain https://t.co/TlJHGuruBZ

Nociscan is now covered by 3 major healthcare payer systems in the UK! Vitality will also cover Nociscan, expanding coverage to 3 of the 4 major private medical insurance groups in the UK. #ACON #ACONW #nasdaq #nociscan #spinecare #lowbackpain https://t.co/oAIsHWErcD

A simple can in an MRI can provide significant personalized biomarker data about the low back discs #Nociscan is the world’s only SaaS platform to transform this data into a simple, streamlined report to optimize the treatment strategy for #lowbackpain #ACON #ACONW #nasdaq

Evidence shows when discs identified by Nociscan are treated as part of the surgical strategy, patients experience a significantly greater success rate following surgery for chronic low back pain. https://t.co/v6BaI0sQC0. #ACON #ACONW #nasdaq #chroniclowbackpain #spinesurgery

Thank you for the invigorating discussion #ASPN2024 last week about the future of diagnosing chronic low back pain and the importance of solutions like #Nociscan in the driving the innovation needed to advance patient care. #ACON #ACONW #nasdaq #spinesurgery #lowbackpain

Ready to learn how the #Nociscan solution can help improve treatment outcomes for patients suffering from chronic #owbackpain Join us at #ASPN Booth 187 to discover the latest clinical data on Nociscan #ACON #ACONW #nasdaq #ASPN2024 #ASPN24 #spine #spinesurgery

Aclarion secures second payer coverage decision by Aviva, expanding Nociscan access to approximately 45% of patients with private payer insurance in the greater London area. https://t.co/Bb5bOwh52Q. #spinesurgery #spine #lowbackpain #nasdaq #ACON #ACONW

Thank you Robert Eastlack MD for the excellent presentation at the State of Spine conference on establishing #Nociscan as the gold standard for non-invasive identification of painful lumbar discs.  https://t.co/t9LeQiQTN6 #ACON #ACONW #nasdaq #microcap #smallcap

Our first payer coverage decision for the Nociscan solution by AXA, a leading provider of private medical insurance in the UK. Congrats to the physicians at the London Clinic who worked to make this positive coverage decision possible! #ACON #ACONW #nasdaq #smallcap #microcap

We are excited to announce that we have extended our commercial agreement with the prestigious London Clinic. Read the full release here https://t.co/c9QMIcqexF #ACON #ACONW #nasdaq #smallcap #microcap

Our patent portfolio is growing! We received our 23rd US patent to further optimize the accuracy and reliability of #Nociscan. Portfolio growth supports potential product expansions into solutions for the breast, prostate, and brain. #ACON #ACONW #nasdaq https://t.co/hmUaXfrrrm

#Nociscan 2.7 is here! We are thrilled to announce that we have released our latest version to enhance physician user-experience, scalability, and security. https://t.co/jPBXwbvpJy #ACON #ACONW #nasdaq #microcap #daytrading #medtechstocks

Excellent and informative poster presentation today by Elisabetta de Rinaldis on the differences between demographic and pain-related features of the spine at #ISSLS2024 #ISSLS #spine #ACON #ACONW #nasdaq #microcap #daytrading #stocks #smallcap